{
  "topicName": "Lipid modification - CVD prevention",
  "topicId": "dc4f1ad8-1fac-4248-9071-a622ca58dd2c",
  "exportId": "91920129-7a9f-4a33-be0f-aa16000365dd",
  "dataId": "c0d63e01-8d34-4e17-b83c-aa17007f13ac",
  "number": 3,
  "dateOfExport": "2019-03-21T07:42:38.6593651+00:00",
  "nextPlannedReviewBy": "2019-12-31T23:59:59+00:00",
  "topicSummary": "Cardiovascular disease (CVD) is an umbrella term for diseases that involve the heart, blood vessels, or both, caused by atherosclerosis",
  "lastRevised": "Last revised in October 2015",
  "terms": [
    {
      "code": "D015228",
      "term": "Hypertriglyceridemia"
    },
    {
      "code": "D050171",
      "term": "Dyslipidemias"
    },
    {
      "code": "D006949",
      "term": "Hyperlipidemias"
    },
    {
      "code": "D008055",
      "term": "Lipids"
    }
  ],
  "clinicalSpecialties": [
    "Cardiovascular",
    "Endocrine and metabolic",
    "Preventative medicine"
  ],
  "aliases": [],
  "topicHtmlObjects": [
    {
      "itemId": "4f3aa19b-67a7-4146-8ff4-119ea3e400f7",
      "parentId": null,
      "rootId": "4f3aa19b-67a7-4146-8ff4-119ea3e400f7",
      "fullItemName": "Summary",
      "htmlHeader": "<!-- begin field 133d749a-7b51-492e-af9a-a78a469fc229 --><h1>Lipid modification - CVD prevention:&nbsp;Summary</h1><!-- end field 133d749a-7b51-492e-af9a-a78a469fc229 -->",
      "htmlStringContent": "REPLACE_ON_SERVE",
      "containerElement": "topicSummary",
      "children": [],
      "depth": 1,
      "pos": 0
    }
  ],
  "latestChanges": [
    {
      "dateFrom": "2015-10-01T00:00:00+01:00",
      "dateTo": "2015-10-31T23:59:59+00:00",
      "title": "Minor update",
      "body": "Immune-mediated necrotizing myopathy (IMNM) has been included as a very rare adverse effect of some statins ABPI Medicines Compendium, 2015c ABPI Medicines Compendium, 2015b."
    },
    {
      "dateFrom": "2015-07-01T00:00:00+01:00",
      "dateTo": "2015-07-31T23:59:59+01:00",
      "title": "Minor update",
      "body": "Minor text change to remove the percentage equivalents of HbA1c mmol/mol values, which are no longer commonly used to diagnose diabetes mellitus."
    },
    {
      "dateFrom": "2015-06-01T00:00:00+01:00",
      "dateTo": "2015-06-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "Further clarification on the use of ezetimibe for the prevention of cardiovascular disease (CVD)."
    },
    {
      "dateFrom": "2015-05-01T00:00:00+01:00",
      "dateTo": "2015-05-31T23:59:59+01:00",
      "title": "Minor update",
      "body": "Following an update to the Summary of Product Characteristics (SPC) for atorvastatin, as advised by the European Medicines Agency EMA, 2015, immune-mediated necrotizing myopathy has been added as a possible adverse effect during or after treatment with atorvastatin (and other statins) ABPI Medicines Compendium, 2015a."
    },
    {
      "dateFrom": "2015-04-01T00:00:00+01:00",
      "dateTo": "2015-04-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "The recommendations on the use of ezetimibe for the prevention of CVD have been amended to reflect recommendations in the National Institute for Health and Care Excellence (NICE) guideline Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE, 2014 and the NICE technology appraisal Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia NICE, 2007."
    },
    {
      "dateFrom": "2015-02-01T00:00:00+00:00",
      "dateTo": "2015-02-28T23:59:59+00:00",
      "title": "Minor update",
      "body": "Typographical errors corrected in the topic."
    },
    {
      "dateFrom": "2014-12-01T00:00:00+00:00",
      "dateTo": "2014-12-31T23:59:59+00:00",
      "title": "Reviewed",
      "body": "The recommendations have been updated in line with recommendations in the revised NICE guideline Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE, 2014. Significant changes to the recommendations include advice on:"
    }
  ]
}
